Associate Professor Liz Caldon

Associate Professor Liz Caldon runs a basic and translational research program on estrogen receptor positive (ER+) breast cancer, basal-like breast cancers and ovarian cancers. She is Head of the Replication and Genome Stability Group at the Garvan Institute of Medical Research. Her group has built models of hormone therapy and CDK4-6 inhibitor resistance to understand the evolution of ER+ breast cancers as they become refractory to standard of care therapies. Specific interests of her group are the understanding of tumour cell evolution through single cell modelling, cell cycle-based therapies, therapy repurposing, and the development of targeted approaches in therapy resistant disease.

Liz is a Cancer Institute NSW Fellow, and a recipient of the Mavis Robertson fellowship from the NBCF. She is an Associate Editor for the journals Oncogenesis and Endocrine Oncology.